BioPharma Resources

Therapeutic area

Kidney and urology

Chronic kidney disease, IgA nephropathy, overactive bladder and BPH. Drugs are placed in areas by keyword matches on their FDA pharmacologic class and approved use, and trials by their listed conditions, so a few land in the wrong area.

Last checked: Nov 19, 2026Source: Drugs@FDA, ClinicalTrials.govMethods & limitations

Approvals since 2023

44

Originals, plus breakthrough or accelerated new uses

Recruiting Phase 2

34

Industry-sponsored

Recruiting Phase 3

29

Industry-sponsored

Recruiting Phase 4 (post-approval)

3

Industry-sponsored

Recent approvals

All
  • Trutakna (Atacicept-Vymj) · Vera Therapeutics Inc. NovelPriority reviewJul 7, 2026

    To reduce proteinuria in adults with primary immunoglobulin A nephropathy at risk for disease progression

  • Utebzi (Tebipenem Pivoxil Hydrobromide) · Glaxosmithkline NovelPriority reviewJun 17, 2026

    To treat complicated urinary tract infections, including pyelonephritis, caused by several susceptible microorganisms in adults who have limited or no alternative oral treatment options

  • Zaynich (Cefepime Hydrochloride, Zidebactam) · Wockhardt Bio AG NovelPriority reviewMay 29, 2026

    To treat complicated urinary tract infections, including pyelonephritis, caused by designated susceptible microorganisms

  • Epinephrine (Epinephrine) · Baxter Hlthcare Corp Mar 30, 2026
  • Flavalta (Epinephrine Bitartrate, Lidocaine Hydrochloride) · Deproco Mar 19, 2026
  • Oziltus (Denosumab-Mobz) · Amneal Pharms LLC Dec 19, 2025
  • Boncresa (Denosumab-Mobz) · Amneal Pharms LLC Dec 19, 2025
  • Lerochol (Lerodalcibep-Liga) · Lib Therapeutics, Inc. NovelDec 12, 2025

    To reduce low-density lipoprotein cholesterol in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia, as an adjunct to diet and exercise

  • Imfinzi (Durvalumab) · Astrazeneca Uk LTD Breakthrough therapyPriority reviewOrphanNov 25, 2025
  • Voyxact (Sibeprenlimab-Szsi) · Otsuka Pharm CO LTD NovelBreakthrough therapyAccelerated approvalPriority reviewNov 25, 2025

    To reduce proteinuria in primary immunoglobulin A nephropathy in adults at risk for disease progression

  • Conexxence (Denosumab-Bnht) · Fresenius Kabi USA LLC Oct 29, 2025
  • Osenvelt (Denosumab-Bmwo) · Celltrion INC Oct 29, 2025
  • Denosumab-Dssb (Denosumab-Dssb) · Samsung Bioepis CO LTD Oct 29, 2025
  • Aukelso (Denosumab-Kyqq) · Biocon Biologics INC Oct 29, 2025
  • Osvyrti (Denosumab-Desu) · Accord Biopharma Inc. Oct 29, 2025

Drugs in development

Investigational drugs in Phase 2 and 3 trials for conditions in this area, most trials first.

All
  • SKB264MK-2870, Sacituzumab TirumotecanPhase 353 trials

    Merck & Co. · Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer, Cervical Cancer

  • CadonilimabAK104Phase 331 trials

    Akeso · Hepatocellular Carcinoma, Gastric / Gastroesophageal Junction Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma

  • AdabelimumabSHR-A2102, SHR2554Phase 320 trials

    Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Advanced Solid Tumors, Prostate Cancer, Advanced Urothelial Carcinoma

  • CagrilintidePhase 320 trials

    Novo Nordisk · Obesity, Overweight, Type 2 Diabetes

  • IanalumabVAY736, VAY736 AIPhase 318 trials

    Novartis · Primary Immune Thrombocytopenia (ITP), Systemic Lupus Erythematosus, Sjogren Syndrome

  • BL-M07D1Phase 317 trials

    Sichuan Baili Pharmaceutical Co., Ltd. · HER2-positive Breast Cancer, Non-squamous Non-small Cell Lung Cancer, Her2-positive/Low-expression Urinary and Digestive Tract Tumors

  • HS-20093Ris-Rez, Risvutatug rezetecanPhase 316 trials

    Hansoh BioMedical R&D Company · Neoplasms, Lung, Sarcoma, Osteosarcoma

  • RetatrutideLY3437943Phase 316 trials

    Eli Lilly · Obesity, Overweight, Type 2 Diabetes

  • VolrustomigMEDI5752Phase 313 trials

    AstraZeneca · Gastric Cancer, Non-small Cell Lung Cancer, Biliary Tract Cancer

  • 9MW2821Phase 311 trials

    Mabwell (Shanghai) Bioscience Co., Ltd. · Urothelial Carcinoma, Advanced Urothelial Carcinoma, Locally Advanced or Metastatic Triple-negative Breast Cancer

  • Savolitinibhmpl-504, AZD6094Phase 311 trials

    AstraZeneca · Carcinoma, Non-small Cell Lung Cancer, Non-Small Cell Lung Cancer

  • YL201Tambotatug Pelitecan, Tam-PeliPhase 311 trials

    MediLink Therapeutics (Suzhou) Co., Ltd. · Advanced Solid Tumor, Small Cell Lung Cancer, Metastatic Pancreatic Cancer

  • ZanzalintinibXL092Phase 311 trials

    Exelixis · Colorectal Cancer, Renal Cell Carcinoma, Head and Neck Squamous Cell Carcinoma

  • HRS-7535Phase 310 trials

    Shandong Suncadia Medicine Co., Ltd. · Type 2 Diabetes, Chronic Kidney Disease, Adults With Heart Failure, Mild Decrease in Ejection Fraction/Preserved Ejection Fraction, and Obesity

  • Intismeran autogeneV940, mRNA-4157Phase 310 trials

    Merck & Co. · Non-small Cell Lung Cancer, Melanoma, Bladder Cancer

Largest recruiting Phase 3 trials

All

More: Kidney and urology news · literature

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.